Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
Identifieur interne : 000484 ( Main/Exploration ); précédent : 000483; suivant : 000485Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
Auteurs : Anbok Lee [Corée du Sud] ; Sunmi Jo [Corée du Sud] ; Changhu Lee [Corée du Sud] ; Hyun-Hee Shin [Corée du Sud] ; Tae Hyun Kim [Corée du Sud] ; Ki Jung Ahn [Corée du Sud] ; Sung-Kwang Park [Corée du Sud] ; Heunglae Cho [Corée du Sud] ; Hye-Kyoung Yoon [Corée du Sud] ; Woo Gyeong Kim [Corée du Sud] ; Jiyoung Park [Corée du Sud] ; Yunseon Choi [Corée du Sud]Source :
- Breast cancer (Tokyo, Japan) [ 1880-4233 ] ; 2019.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Antinéoplasiques immunologiques (pharmacologie), Antinéoplasiques immunologiques (usage thérapeutique), Diabète de type 2 (complications), Diabète de type 2 (mortalité), Diabète de type 2 (traitement médicamenteux), Femelle (MeSH), Humains (MeSH), Neuréguline-1 (métabolisme), Pronostic (MeSH), Récepteur ErbB-2 (antagonistes et inhibiteurs), Récepteur ErbB-2 (métabolisme), Récepteur ErbB-3 (métabolisme), Récidive (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Survie sans rechute (MeSH), Taux de survie (MeSH), Thérapie moléculaire ciblée (MeSH), Trastuzumab (pharmacologie), Trastuzumab (usage thérapeutique), Tumeurs du sein (chirurgie), Tumeurs du sein (complications), Tumeurs du sein (mortalité), Tumeurs du sein (traitement médicamenteux), Études de suivi (MeSH).
- MESH :
- antagonistes et inhibiteurs : Récepteur ErbB-2.
- chirurgie : Tumeurs du sein.
- mortalité : Diabète de type 2, Tumeurs du sein.
- métabolisme : Diabète de type 2, Neuréguline-1, Récepteur ErbB-2, Récepteur ErbB-3, Tumeurs du sein.
- pharmacologie : Antinéoplasiques immunologiques, Trastuzumab.
- traitement médicamenteux : Diabète de type 2, Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques immunologiques, Trastuzumab.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Pronostic, Récidive, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie, Thérapie moléculaire ciblée, Études de suivi.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antineoplastic Agents, Immunological (pharmacology), Antineoplastic Agents, Immunological (therapeutic use), Breast Neoplasms (complications), Breast Neoplasms (drug therapy), Breast Neoplasms (mortality), Breast Neoplasms (surgery), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (drug therapy), Diabetes Mellitus, Type 2 (mortality), Disease-Free Survival (MeSH), Female (MeSH), Follow-Up Studies (MeSH), Humans (MeSH), Middle Aged (MeSH), Molecular Targeted Therapy (MeSH), Neuregulin-1 (metabolism), Prognosis (MeSH), Receptor, ErbB-2 (antagonists & inhibitors), Receptor, ErbB-2 (metabolism), Receptor, ErbB-3 (metabolism), Recurrence (MeSH), Survival Rate (MeSH), Trastuzumab (pharmacology), Trastuzumab (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Receptor, ErbB-2.
- chemical , metabolism : Neuregulin-1, Receptor, ErbB-2, Receptor, ErbB-3.
- chemical , pharmacology : Antineoplastic Agents, Immunological, Trastuzumab.
- chemical , therapeutic use : Antineoplastic Agents, Immunological, Trastuzumab.
- complications : Breast Neoplasms, Diabetes Mellitus, Type 2.
- drug therapy : Breast Neoplasms, Diabetes Mellitus, Type 2.
- mortality : Breast Neoplasms, Diabetes Mellitus, Type 2.
- surgery : Breast Neoplasms.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Follow-Up Studies, Humans, Middle Aged, Molecular Targeted Therapy, Prognosis, Recurrence, Survival Rate.
Abstract
PURPOSE
Recent studies revealed that metabolic stress influences the outcomes of breast cancer treatment. We sought to evaluate the prognostic effect of type 2 diabetes and find the molecular mechanism of relapses in postoperative HER-2+ breast cancer patients treated with HER-2 targeted therapy.
MATERIALS AND METHODS
We evaluated 190 HER-2+ breast cancer patients (pT1-4N0-2M0) who were treated with surgical resection and trastuzumab (HER-2 targeted therapy) between 2006 and 2015. Survival outcomes and failure patterns were compared between such patients with (n = 12) and without (n = 178) type 2 diabetes.
RESULTS
The median follow-up period was 42.4 months (range 12.0-124.7 months). Twenty-one patients (11.1%) showed relapse (including nine patients with locoregional failure), and three patients (1.6%) died as a result of cancer relapse. One-third of the patients with diabetes experienced relapse (4/12, 33.3%). The 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.7% and 98.6%, respectively. Diabetic patients showed shorter DFS compared with non-diabetic patients (p = 0.006, 74.1% vs. 91.9%). OS was also shorter in diabetic patients compared with non-diabetic patients (p = 0.017, 91.7% vs. 99.1%). Of our interest, the levels of HER-3 and its ligand neuregulin-1 were significantly increased in the tumor specimen in HER-2+ breast cancer patients suffering with type 2 diabetes than that in the euglycemic control group.
CONCLUSIONS
Type 2 diabetes was associated with detrimental effects on survival in postoperative HER-2+ breast cancer patients who were treated with trastuzumab. The poor prognostic effect of diabetes in HER-2+ breast cancer patients could be associated with the high levels of HER-3 and neuregulin 1, thus it should be considered and evaluated more.
DOI: 10.1007/s12282-019-00967-2
PubMed: 30927244
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.</title><author><name sortKey="Lee, Anbok" sort="Lee, Anbok" uniqKey="Lee A" first="Anbok" last="Lee">Anbok Lee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Jo, Sunmi" sort="Jo, Sunmi" uniqKey="Jo S" first="Sunmi" last="Jo">Sunmi Jo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Changhu" sort="Lee, Changhu" uniqKey="Lee C" first="Changhu" last="Lee">Changhu Lee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan</wicri:regionArea><wicri:noRegion>Ulsan</wicri:noRegion></affiliation></author><author><name sortKey="Shin, Hyun Hee" sort="Shin, Hyun Hee" uniqKey="Shin H" first="Hyun-Hee" last="Shin">Hyun-Hee Shin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan</wicri:regionArea><wicri:noRegion>Ulsan</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Tae Hyun" sort="Kim, Tae Hyun" uniqKey="Kim T" first="Tae Hyun" last="Kim">Tae Hyun Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Ahn, Ki Jung" sort="Ahn, Ki Jung" uniqKey="Ahn K" first="Ki Jung" last="Ahn">Ki Jung Ahn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Park, Sung Kwang" sort="Park, Sung Kwang" uniqKey="Park S" first="Sung-Kwang" last="Park">Sung-Kwang Park</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Cho, Heunglae" sort="Cho, Heunglae" uniqKey="Cho H" first="Heunglae" last="Cho">Heunglae Cho</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Yoon, Hye Kyoung" sort="Yoon, Hye Kyoung" uniqKey="Yoon H" first="Hye-Kyoung" last="Yoon">Hye-Kyoung Yoon</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Woo Gyeong" sort="Kim, Woo Gyeong" uniqKey="Kim W" first="Woo Gyeong" last="Kim">Woo Gyeong Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Park, Jiyoung" sort="Park, Jiyoung" uniqKey="Park J" first="Jiyoung" last="Park">Jiyoung Park</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea. jpark@unist.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan</wicri:regionArea><wicri:noRegion>Ulsan</wicri:noRegion></affiliation></author><author><name sortKey="Choi, Yunseon" sort="Choi, Yunseon" uniqKey="Choi Y" first="Yunseon" last="Choi">Yunseon Choi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea. rtyoon@gmail.com.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30927244</idno><idno type="pmid">30927244</idno><idno type="doi">10.1007/s12282-019-00967-2</idno><idno type="wicri:Area/Main/Corpus">000432</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000432</idno><idno type="wicri:Area/Main/Curation">000432</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000432</idno><idno type="wicri:Area/Main/Exploration">000432</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.</title><author><name sortKey="Lee, Anbok" sort="Lee, Anbok" uniqKey="Lee A" first="Anbok" last="Lee">Anbok Lee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Jo, Sunmi" sort="Jo, Sunmi" uniqKey="Jo S" first="Sunmi" last="Jo">Sunmi Jo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Changhu" sort="Lee, Changhu" uniqKey="Lee C" first="Changhu" last="Lee">Changhu Lee</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan</wicri:regionArea><wicri:noRegion>Ulsan</wicri:noRegion></affiliation></author><author><name sortKey="Shin, Hyun Hee" sort="Shin, Hyun Hee" uniqKey="Shin H" first="Hyun-Hee" last="Shin">Hyun-Hee Shin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan</wicri:regionArea><wicri:noRegion>Ulsan</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Tae Hyun" sort="Kim, Tae Hyun" uniqKey="Kim T" first="Tae Hyun" last="Kim">Tae Hyun Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Ahn, Ki Jung" sort="Ahn, Ki Jung" uniqKey="Ahn K" first="Ki Jung" last="Ahn">Ki Jung Ahn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Park, Sung Kwang" sort="Park, Sung Kwang" uniqKey="Park S" first="Sung-Kwang" last="Park">Sung-Kwang Park</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Cho, Heunglae" sort="Cho, Heunglae" uniqKey="Cho H" first="Heunglae" last="Cho">Heunglae Cho</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Yoon, Hye Kyoung" sort="Yoon, Hye Kyoung" uniqKey="Yoon H" first="Hye-Kyoung" last="Yoon">Hye-Kyoung Yoon</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Woo Gyeong" sort="Kim, Woo Gyeong" uniqKey="Kim W" first="Woo Gyeong" last="Kim">Woo Gyeong Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author><author><name sortKey="Park, Jiyoung" sort="Park, Jiyoung" uniqKey="Park J" first="Jiyoung" last="Park">Jiyoung Park</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea. jpark@unist.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan</wicri:regionArea><wicri:noRegion>Ulsan</wicri:noRegion></affiliation></author><author><name sortKey="Choi, Yunseon" sort="Choi, Yunseon" uniqKey="Choi Y" first="Yunseon" last="Choi">Yunseon Choi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea. rtyoon@gmail.com.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan</wicri:regionArea><wicri:noRegion>Busan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Breast cancer (Tokyo, Japan)</title><idno type="eISSN">1880-4233</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antineoplastic Agents, Immunological (pharmacology)</term><term>Antineoplastic Agents, Immunological (therapeutic use)</term><term>Breast Neoplasms (complications)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (mortality)</term><term>Breast Neoplasms (surgery)</term><term>Diabetes Mellitus, Type 2 (complications)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Diabetes Mellitus, Type 2 (mortality)</term><term>Disease-Free Survival (MeSH)</term><term>Female (MeSH)</term><term>Follow-Up Studies (MeSH)</term><term>Humans (MeSH)</term><term>Middle Aged (MeSH)</term><term>Molecular Targeted Therapy (MeSH)</term><term>Neuregulin-1 (metabolism)</term><term>Prognosis (MeSH)</term><term>Receptor, ErbB-2 (antagonists & inhibitors)</term><term>Receptor, ErbB-2 (metabolism)</term><term>Receptor, ErbB-3 (metabolism)</term><term>Recurrence (MeSH)</term><term>Survival Rate (MeSH)</term><term>Trastuzumab (pharmacology)</term><term>Trastuzumab (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antinéoplasiques immunologiques (pharmacologie)</term><term>Antinéoplasiques immunologiques (usage thérapeutique)</term><term>Diabète de type 2 (complications)</term><term>Diabète de type 2 (mortalité)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Neuréguline-1 (métabolisme)</term><term>Pronostic (MeSH)</term><term>Récepteur ErbB-2 (antagonistes et inhibiteurs)</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Récepteur ErbB-3 (métabolisme)</term><term>Récidive (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Survie sans rechute (MeSH)</term><term>Taux de survie (MeSH)</term><term>Thérapie moléculaire ciblée (MeSH)</term><term>Trastuzumab (pharmacologie)</term><term>Trastuzumab (usage thérapeutique)</term><term>Tumeurs du sein (chirurgie)</term><term>Tumeurs du sein (complications)</term><term>Tumeurs du sein (mortalité)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études de suivi (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neuregulin-1</term><term>Receptor, ErbB-2</term><term>Receptor, ErbB-3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents, Immunological</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents, Immunological</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur ErbB-2</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Diabète de type 2</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Diabète de type 2</term><term>Neuréguline-1</term><term>Récepteur ErbB-2</term><term>Récepteur ErbB-3</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques immunologiques</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques immunologiques</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Middle Aged</term><term>Molecular Targeted Therapy</term><term>Prognosis</term><term>Recurrence</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Pronostic</term><term>Récidive</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Thérapie moléculaire ciblée</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>Recent studies revealed that metabolic stress influences the outcomes of breast cancer treatment. We sought to evaluate the prognostic effect of type 2 diabetes and find the molecular mechanism of relapses in postoperative HER-2+ breast cancer patients treated with HER-2 targeted therapy.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>We evaluated 190 HER-2+ breast cancer patients (pT1-4N0-2M0) who were treated with surgical resection and trastuzumab (HER-2 targeted therapy) between 2006 and 2015. Survival outcomes and failure patterns were compared between such patients with (n = 12) and without (n = 178) type 2 diabetes.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The median follow-up period was 42.4 months (range 12.0-124.7 months). Twenty-one patients (11.1%) showed relapse (including nine patients with locoregional failure), and three patients (1.6%) died as a result of cancer relapse. One-third of the patients with diabetes experienced relapse (4/12, 33.3%). The 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.7% and 98.6%, respectively. Diabetic patients showed shorter DFS compared with non-diabetic patients (p = 0.006, 74.1% vs. 91.9%). OS was also shorter in diabetic patients compared with non-diabetic patients (p = 0.017, 91.7% vs. 99.1%). Of our interest, the levels of HER-3 and its ligand neuregulin-1 were significantly increased in the tumor specimen in HER-2+ breast cancer patients suffering with type 2 diabetes than that in the euglycemic control group.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Type 2 diabetes was associated with detrimental effects on survival in postoperative HER-2+ breast cancer patients who were treated with trastuzumab. The poor prognostic effect of diabetes in HER-2+ breast cancer patients could be associated with the high levels of HER-3 and neuregulin 1, thus it should be considered and evaluated more.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30927244</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1880-4233</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Breast cancer (Tokyo, Japan)</Title><ISOAbbreviation>Breast Cancer</ISOAbbreviation></Journal><ArticleTitle>Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.</ArticleTitle><Pagination><MedlinePgn>672-680</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12282-019-00967-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Recent studies revealed that metabolic stress influences the outcomes of breast cancer treatment. We sought to evaluate the prognostic effect of type 2 diabetes and find the molecular mechanism of relapses in postoperative HER-2+ breast cancer patients treated with HER-2 targeted therapy.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We evaluated 190 HER-2+ breast cancer patients (pT1-4N0-2M0) who were treated with surgical resection and trastuzumab (HER-2 targeted therapy) between 2006 and 2015. Survival outcomes and failure patterns were compared between such patients with (n = 12) and without (n = 178) type 2 diabetes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median follow-up period was 42.4 months (range 12.0-124.7 months). Twenty-one patients (11.1%) showed relapse (including nine patients with locoregional failure), and three patients (1.6%) died as a result of cancer relapse. One-third of the patients with diabetes experienced relapse (4/12, 33.3%). The 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.7% and 98.6%, respectively. Diabetic patients showed shorter DFS compared with non-diabetic patients (p = 0.006, 74.1% vs. 91.9%). OS was also shorter in diabetic patients compared with non-diabetic patients (p = 0.017, 91.7% vs. 99.1%). Of our interest, the levels of HER-3 and its ligand neuregulin-1 were significantly increased in the tumor specimen in HER-2+ breast cancer patients suffering with type 2 diabetes than that in the euglycemic control group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Type 2 diabetes was associated with detrimental effects on survival in postoperative HER-2+ breast cancer patients who were treated with trastuzumab. The poor prognostic effect of diabetes in HER-2+ breast cancer patients could be associated with the high levels of HER-3 and neuregulin 1, thus it should be considered and evaluated more.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Anbok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Sunmi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Changhu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Hyun-Hee</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Hyun</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Ki Jung</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sung-Kwang</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Heunglae</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hye-Kyoung</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Woo Gyeong</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jiyoung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Life Sciences, Ulsan National Institutes of Science and Technology, Ulsan, South Korea. jpark@unist.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yunseon</ForeName><Initials>Y</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-1397-6753</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea. rtyoon@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI14C1277</GrantID><Agency>Korea Health Technology R&D Project</Agency><Country></Country></Grant><Grant><GrantID>2017M3A9C4065956</GrantID><Agency>Ministry of Science, ICT and Future Planning</Agency><Country></Country></Grant><Grant><GrantID>NRF-2018R1A2B6003878</GrantID><Agency>National Research Council of Science and Technology</Agency><Country></Country></Grant><Grant><GrantID>1.180018.01</GrantID><Agency>Ulsan National Institute of Science and Technology</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Breast Cancer</MedlineTA><NlmUniqueID>100888201</NlmUniqueID><ISSNLinking>1340-6868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C581292">ERBB3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020893" MajorTopicYN="N">Receptor, ErbB-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">HER-2 positive breast cancer</Keyword><Keyword MajorTopicYN="N">Prognostic factor</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Trastuzumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30927244</ArticleId><ArticleId IdType="doi">10.1007/s12282-019-00967-2</ArticleId><ArticleId IdType="pii">10.1007/s12282-019-00967-2</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country></list><tree><country name="Corée du Sud"><noRegion><name sortKey="Lee, Anbok" sort="Lee, Anbok" uniqKey="Lee A" first="Anbok" last="Lee">Anbok Lee</name></noRegion><name sortKey="Ahn, Ki Jung" sort="Ahn, Ki Jung" uniqKey="Ahn K" first="Ki Jung" last="Ahn">Ki Jung Ahn</name><name sortKey="Cho, Heunglae" sort="Cho, Heunglae" uniqKey="Cho H" first="Heunglae" last="Cho">Heunglae Cho</name><name sortKey="Choi, Yunseon" sort="Choi, Yunseon" uniqKey="Choi Y" first="Yunseon" last="Choi">Yunseon Choi</name><name sortKey="Jo, Sunmi" sort="Jo, Sunmi" uniqKey="Jo S" first="Sunmi" last="Jo">Sunmi Jo</name><name sortKey="Kim, Tae Hyun" sort="Kim, Tae Hyun" uniqKey="Kim T" first="Tae Hyun" last="Kim">Tae Hyun Kim</name><name sortKey="Kim, Woo Gyeong" sort="Kim, Woo Gyeong" uniqKey="Kim W" first="Woo Gyeong" last="Kim">Woo Gyeong Kim</name><name sortKey="Lee, Changhu" sort="Lee, Changhu" uniqKey="Lee C" first="Changhu" last="Lee">Changhu Lee</name><name sortKey="Park, Jiyoung" sort="Park, Jiyoung" uniqKey="Park J" first="Jiyoung" last="Park">Jiyoung Park</name><name sortKey="Park, Sung Kwang" sort="Park, Sung Kwang" uniqKey="Park S" first="Sung-Kwang" last="Park">Sung-Kwang Park</name><name sortKey="Shin, Hyun Hee" sort="Shin, Hyun Hee" uniqKey="Shin H" first="Hyun-Hee" last="Shin">Hyun-Hee Shin</name><name sortKey="Yoon, Hye Kyoung" sort="Yoon, Hye Kyoung" uniqKey="Yoon H" first="Hye-Kyoung" last="Yoon">Hye-Kyoung Yoon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000484 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000484 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30927244
|texte= Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30927244" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |